Trials & Tribulations A study measures the long-term downside of prostate cancer screeningA paper in JAMA Oncology focuses on the harms of overscreening, overdiagnosis, and overtreatment November 08, 2024Vol.50 No.42By Otis W. Brawley
Trials & Tribulations Addressing high cancer mortality in Native Hawaiian and Pacific Islander populationsA call for equity in cancer research November 01, 2024Vol.50 No.41By Naoto T. Ueno
Trials & Tribulations Cancer clinical trials shouldn’t discriminate—but they do October 11, 2024Vol.50 No.38By Erin Miller
Trials & Tribulations A simple intervention could help address overlooked pain among older adults with cancer in rural America September 13, 2024Vol.50 No.34By Megan J. Shen
Trials & Tribulations Is gastrectomy indicated?A study recently published in JAMA suggests lower lifetime gastric cancer risk for CDH1 mutation carriers. Will this lead to changes in management recommendations? September 06, 2024Vol.50 No.33By Rebecca Sutphen, Sue Friedman and Jon Florin
Trials & Tribulations Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC August 02, 2024Vol.50 No.31By Donald A. Berry
Trials & Tribulations Better oncology drug management could lead to improved outcomes, lower costs July 26, 2024Vol.50 No.30By Matt Ingram
Trials & Tribulations The thorny road to drug approval for myelodysplastic syndromes June 14, 2024Vol.50 No.24By Mikkael A. Sekeres
Trials & Tribulations Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists June 07, 2024Vol.50 No.23By Rebecca Sutphen
Trials & Tribulations Are we focused on the wrong risk type in genetic screening?Breast cancer screening study shows new paths to population screening May 24, 2024Vol.50 No.21By Cassie Hajek
